아스트라제네카의 다토포타맙 데룩스테칸, 미국에서 전이성 폐암 치료에 대한 신속 심사 대상으로 지정
This Fast Track designation could expedite the development and review of datopotamab deruxtecan, potentially bringing a new treatment option to a large patient population with advanced lung cancer who have limited choices after initial therapies fail.
AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan received US FDA Fast Track designation for advanced or metastatic non-squamous NSCLC patients who have undergone prior systemic therapy.
아스트라제네카와 다이이치산쿄의 TROP2 표적 항체-약물 접합체인 다토포타맙 데룩스테칸이 이전 전신 치료를 받은 국소 진행성 또는 전이성 비편평 비소세포폐암(NSCLC) 성인 환자 치료에 대해 미국 FDA로부터 신속 심사 대상으로 지정되었습니다. 이 지정은 표준 화학요법 대비 무진행 생존기간의 유의미한 개선을 보인 TROPION-Lung01 3상 임상시험 결과를 기반으로 합니다.
This Fast Track designation could expedite the development and review of datopotamab deruxtecan, potentially bringing a new treatment option to a large patient population with advanced lung cancer who have limited choices after initial therapies fail. It strengthens AstraZeneca and Daiichi Sankyo's position in the competitive ADC market for oncology.
Where this signal fits in the broader landscape.
https://www.astrazeneca.com/media-centre/press-releases/2026/datopotamab-deruxtecan-granted-fast-track-designation-in-us-for-metastatic-non-small-cell-lung-cancer.html
Read Full SourceGet curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
Sign in to save notes on signals.
로그인